Quince Therapeutics (QNCX) has released an update to notify the public and investors about its officers.
On January 23, 2024, Quince Therapeutics, Inc. decided not to increase executive officer salaries but approved stock option grants effective February 1, 2024, under the 2019 Equity Incentive Plan. These options will vest monthly over four years, contingent on continued service. The 2023 bonuses and Option Awards include $302,500 and 1,500,000 options for the CEO, $70,000 and 145,000 for the President, and $178,500 and 600,000 for the Chief Business Officer and COO.
For further insights into QNCX corporate activity, check out TipRanks’ Insiders Trading Activity page.
